Overview
On 16 November 2004, orphan designation (EU/3/04/245) was granted by the European Commission to PharmaMar SA Sociedad Unipersonal, Spain, for aplidine for the treatment of multiple myeloma.
Key facts
Active substance |
Aplidine
|
Intended use |
Treatment of multiple myeloma
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/04/245
|
Date of designation |
16/11/2004
|
Sponsor |
Phama Mar S.A. Sociedad Unipersonal
Polígono Industrial La Mina Avda de los Reyes 1 E-28770 Colmenar Viejo Madrid Spain Telephone: +34 91 84 66 000 Telefax: +34 91 84 66 001 E-mail: pharmamar@pharmamar.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: